X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection

mBio

Volumn 4, Issue 4, 2013, Pages

  Szymczak, Wendy A ^a   Davis, Michael J ^b,c   Lundy, Steven K ^b   Dufaud, Chad ^d   Olszewski, Michal ^b,c   Pirofski, Liise Anne ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IMMUNOGLOBULIN M;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BRAIN INFECTION; BTK GENE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; EXPERIMENTAL MOUSE; FUNGAL BRAIN INFECTION; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; GENE; GOMORI SILVER STAINING; HISTOPATHOLOGY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFECTION SENSITIVITY; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS MACROPHAGE; LUNG MYCOSIS; LYMPHOCYTE DEPLETION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM CELL; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; STAINING; SURVIVAL RATE; X CHROMOSOME LINKED DISORDER;

FILOBASIDIELLA NEOFORMANS; MUS;

EID: 84883337331     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00265-13     Document Type: Article

References (75)

1. McClelland EE, Nicola AM, Prados-Rosales R, Casadevall A. 2010. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J. Clin. Invest. 120:1355-1361.
2. Martinez LR, Moussai D, Casadevall A. 2004. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect. Immun. 72:3674-3679.
3. Rivera J, Mukherjee J, Weiss LM, Casadevall A. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168:3419-3427.
4. Miller GP, Kohl S. 1983. Antibody-dependent leukocyte killing of Cryptococcus neoformans. J. Immunol. 131:1455-1459.
5. Feldmesser M, Mednick A, Casadevall A. 2002. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70:1571-1580.
6. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. 2010. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 184: 5755-5767.
7. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, Proietti C, Bistoni F, Cassone A, Vecchiarelli A. 2007. An anti-betaglucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75:5085-5094.
8. Sundstrom JB, Cherniak R. 1992. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect. Immun. 60:4080-4087.
9. Maitta RW, Datta K, Chang Q, Luo RX, Witover B, Subramaniam K, Pirofski LA. 2004. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect. Immun. 72:4810-4818.
10. Taborda CP, Casadevall A. 2001. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J. Immunol. 166:2100-2107.
11. Subramaniam K, Metzger B, Hanau LH, Guh A, Rucker L, Badri S, Pirofski LA. 2009. IgM(+) memory B cell expression predicts HIVassociated cryptococcosis status. J. Infect. Dis. 200:244-251.
12. Ha SA, Tsuji M, Suzuki K, Meek B, Yasuda N, Kaisho T, Fagarasan S. 2006. Regulation of B1 cell migration by signals through Toll-like receptors. J. Exp. Med. 203:2541-2550.
13. Choi YS, Dieter JA, Rothaeusler K, Luo Z, Baumgarth N. 2012. B-1 cells in the bone marrow are a significant source of natural IgM. Eur. J. Immunol. 42:120-129.
14. Ghosn EE, Russo M, Almeida SR. 2006. Nitric oxide-dependent killing of Cryptococcus neoformans by B-1-derived mononuclear phagocyte. J. Leukoc. Biol. 80:36-44.
15. Kantor AB, Stall AM, Adams S, Herzenberg LA, Herzenberg LA. 1992. Differential development of progenitor activity for three B-cell lineages. Proc. Natl. Acad. Sci. U. S. A. 89:3320-3324.
16. Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, Zheng M, Plevy S, Bengtén E, Kolls JK. 2010. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J. Exp. Med. 207:2907-2919.
17. Thurnheer MC, Zuercher AW, Cebra JJ, Bos NA. 2003. B1 cells contribute to serum IgM, but not to intestinal IgA, production in gnotobiotic Ig allotype chimeric mice. J. Immunol. 170:4564-4571.
18. Haas KM, Poe JC, Steeber DA, Tedder TF. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
19. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Herzenberg LA, Vogel SN. 2009. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc. Natl. Acad. Sci. U. S. A. 106:4343-4348.
20. Yang Y, Ghosn EE, Cole LE, Obukhanych TV, Sadate-Ngatchou P, Vogel SN, Herzenberg LA, Herzenberg LA. 2012. Antigen-specific antibody responses in B-1a and their relationship to natural immunity. Proc. Natl. Acad. Sci. U. S. A. 109:5382-5387.
21. Parra D, Rieger AM, Li J, Zhang YA, Randall LM, Hunter CA, Barreda DR, Sunyer JO. 2012. Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and present phagocytosed antigen to CD4+ T cells. J. Leukoc. Biol. 91:525-536.
22. Baumgarth N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 11:34-46.
23. Ghosn EE, Yamamoto R, Hamanaka S, Yang Y, Herzenberg LA, Nakauchi H, Herzenberg LA. 2012. Distinct B-cell lineage commitment distinguishes adult bone marrow hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 109:5394-5398.
24. Yang Y, Ghosn EE, Cole LE, Obukhanych TV, Sadate-Ngatchou P, Vogel SN, Herzenberg LA, Herzenberg LA. 2012. Antigen-specific memory in B-1a and its relationship to natural immunity. Proc. Natl. Acad. Sci. U. S. A. 109:5388-5393.
25. Alugupalli KR, Gerstein RM, Chen J, Szomolanyi-Tsuda E, Woodland RT, Leong JM. 2003. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J. Immunol. 170:3819-3827.
26. Rohatgi S, Pirofski LA. 2012. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J. Immunol. 189:5820-5830.
27. Almeida SR, Aroeira LS, Frymuller E, Dias MA, Bogsan CS, Lopes JD, Mariano M. 2001. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int. Immunol. 13:1193-1201.
28. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG, et al. 1993. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261:358-361.
29. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Müller S, Kantor AB, Herzenberg LA, Rosen FS, Siderase P. 1995. Defective B cell development and function in Btk-deficient mice. Immunity 3:283-299.
30. Prior L, Pierson S, Woodland RT, Riggs J. 1994. Rapid restoration of B-cell function in XID mice by intravenous transfer of peritoneal cavity B cells. Immunology 83:180-183.
31. Amsbaugh DF, Hansen CT, Prescott B, Stashak PW, Barthold DR, Baker PJ. 1972. Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J. Exp. Med. 136:931-949.
32. Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. 1985. Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun. 47:282-287.
33. Russo RT, Mariano M. 2010. B-1 cell protective role in murine primary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunobiology 215:1005-1014.
34. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, Rousseau S. 2010. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J. Immunol. 184:4531-4537.
35. Szymczak WA, Sellers RS, Pirofski LA. 2012. IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and-dependent mechanisms. Am. J. Pathol. 180:1547-1559.
36. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. 2011. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One 6:e17204. doi: 10.1371/journal.pone.0017204.
37. Jain AV, Zhang Y, Fields WB, McNamara DA, Choe MY, Chen GH, Erb-Downward J, Osterholzer JJ, Toews GB, Huffnagle GB, Olszewski MA. 2009. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infect. Immun. 77:5389-5399.
38. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, Barletta R. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694-705.
39. Mond JJ, Lieberman R, Inman JK, Mosier DE, Paul WE. 1977. Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers. J. Exp. Med. 146:1138-1142.
40. Briles DE, Nahm M, Marion TN, Perlmutter RM, Davie JM. 1982. Streptococcal group A carbohydrate has properties of both a thymusindependent (TI-2) and a thymus-dependent antigen. J. Immunol. 128: 2032-2035.
41. Julius P, Jr, Kaga M, Palmer Y, Vyas V, Prior L, Delice D, Riggs J. 1997. Recipient age determines the success of intraperitoneal transplantation of peritoneal cavity B cells. Immunology 91:383-390.
42. Lundy SK, Berlin AA, Martens TF, Lukacs NW. 2005. Deficiency of regulatory B cells increases allergic airway inflammation. Inflamm. Res. 54:514-521.
43. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. 2005. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J. Immunol. 174: 1027-1036.
44. Piehler D, Stenzel W, Grahnert A, Held J, Richter L, Köhler G, Richter T, Eschke M, Alber G, Müller U. 2011. Eosinophils contribute to IL-4 production and shape the T-helper cytokine profile and inflammatory response in pulmonary cryptococcosis. Am. J. Pathol. 179:733-744.
45. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. 2005. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174:6346-6356.
46. Stenzel W, Muller U, Kohler G, Heppner FL, Blessing M, McKenzie AN, Brombacher F, Alber G. 2009. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am. J. Pathol. 174:486-496.
47. Mangla A, Khare A, Vineeth V, Panday NN, Mukhopadhyay A, Ravindran B, Bal V, George A, Rath S. 2004. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 104:1191-1197.
48. Mukhopadhyay S, Mohanty M, Mangla A, George A, Bal V, Rath S, Ravindran B. 2002. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J. Immunol. 168:2914-2921.
49. Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, Takagi M, Mizutani S, Morio T. 2012. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat. Immunol. 13:369-378.
50. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. 1998. A critical role of natural immunoglobulinMin immediate defense against systemic bacterial infection. J. Exp. Med. 188:2381-2386.
51. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
52. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. 2000. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192:271-280.
53. Donahue AC, Hess KL, Ng KL, Fruman DA. 2004. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. Int. Immunol. 16:1789-1798.
54. Choi YS, Baumgarth N. 2008. Dual role for B-1a cells in immunity to influenza virus infection. J. Exp. Med. 205:3053-3064.
55. Foote JB, Mahmoud TI, Vale AM, Kearney JF. 2012. Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells. J. Immunol. 188:57-67.
56. Racine R, McLaughlin M, Jones DD, Wittmer ST, MacNamara KC, Woodland DL, Winslow GM. 2011. IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J. Immunol. 186:1011-1021.
57. Carroll SF, Loredo Osti JC, Guillot L, Morgan K, Qureshi ST. 2008. Sex differences in the genetic architecture of susceptibility to Cryptococcus neoformans pulmonary infection. Genes Immun. 9:536-545.
58. Maglione PJ, Xu J, Chan J. 2007. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J. Immunol. 178:7222-7234.
59. Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. 2010. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guérin vaccination against tuberculosis infection in mice. J. Immunol. 184:1227-1234.
60. Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C, Wormley FL. 2009. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4:e6854. doi: 10.1371/ journal.pone.0006854.
61. Feldmesser M, Kress Y, Casadevall A. 2001. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147:2355-2365.
62. Cruickshank JG, Cavill R, Jelbert M. 1973. Cryptococcus neoformans of unusual morphology. Appl. Microbiol. 25:309-312.
63. Love GL, Boyd GD, Greer DL. 1985. Large Cryptococcus neoformans isolated from brain abscess. J. Clin. Microbiol. 22:1068-1070.
64. Zaragoza O, Taborda CP, Casadevall A. 2003. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immunol. 33: 1957-1967.
65. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodríguez-Tudela JL, Casadevall A. 2008. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10:2043-2057.
66. Zaragoza O, García-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodríguez-Tudela JL, Casadevall A. 2010. Fungal cell gigantism during mammalian infection. PLoS Pathog. 6:e1000945. doi: 10.1371/ journal.ppat.1000945.
67. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chrétien F, Heitman J, Dromer F, Nielsen K. 2010. Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog. 6:e1000953. doi: 10.1371/journal.ppat.1000953.
68. Okagaki LH, Nielsen K. 2012. Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot. Cell 11:820-826.
69. Crabtree JN, Okagaki LH, Wiesner DL, Strain AK, Nielsen JN, Nielsen K. 2012. Titan cell production enhances the virulence of Cryptococcus neoformans. Infect. Immun. 80:3776-3785.
70. Byrne JC, Ní Gabhann J, Stacey KB, Coffey BM, McCarthy E, Thomas W, Jefferies CA. 2013. Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin. J. Immunol. 190:5207-5215.
71. Amoras AL, Kanegane H, Miyawaki T, Vilela MM. 2003. Defective Fc-, CR1-and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J. Investig. Allergol. Clin. Immunol. 13:181-188.
72. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. 2013. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31:88-94.
73. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ. 2011. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13:R115. doi: 10.1186/ar3400.
74. Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, Thaiss F, Rimmelzwaan GF, Elewaut D, Delsing D, van Loo PF, Hendriks RW. 2012. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119: 3744-3756.
75. Rohrer J, Conley ME. 1999. Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood 94:3358-3365.